"The voice for cancer physicians and their patients in Massachusetts."

FDA Approval for Expanded Use of ibrutinib (imbruvica)

05 Feb 2019 1:50 PM | Anonymous

The U.S. Food and Drug Administration approved the expanded use of ibrutinib (imbruvica; Pharmacyclics) in combination with obinutuzumab for adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). Read full press release.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software